论文部分内容阅读
对冠心病慢性心力衰竭患者应用不同剂量阿托伐他汀与瑞舒伐他汀的临床疗效对比及其安全性进行分析.从该院2015年1月至2017年1月期间收治的冠心病慢性心力衰竭患者中抽取200例, 随机、均等分为阿托伐他汀常规剂量组 (阿托伐他汀常规剂量治疗) 、瑞舒伐他汀常规剂量组 (瑞舒伐他汀常规剂量治疗) 、阿托伐他汀负荷剂量组 (阿托伐他汀负荷剂量治疗) 、瑞舒伐他汀负荷剂量组 (瑞舒伐他汀负荷剂量治疗).对比治疗6个月后不同组别血脂指标、临床效果与不良反应情况.治疗前4组TG、TC、LDL-C水平差异不明显 (P>0.05), 治疗后均有所降低 (P0.05).治疗前4组HDL-C水平差异不明显 (P>0.05), 治疗后均有所升高 (P0.05).瑞舒伐他汀常规剂量组总有效率明显比阿托伐他汀常规剂量组、瑞舒伐他汀负荷剂量组高 (P 0.05) HDL-C levels were not significantly different (P> 0.05) before treatment, after treatment were increased (P < 0.05), but Rosuvastatin conventional dose group was significantly higher than those of Atorvastatin conventional dose group, Rosuvastatin loading dose group (P < 0.05).Atorvastatin loading dose group was significantly higher than Atorvastatin normal dose group and Rosuvastatin loading dose group (P 0.05).Compared with the normal dose of Rosuvastatin and Rosuvastatin loading dose group, the total effective rate of Rosuvastatin conventional dose group was significantly higher than that of Rosuvastatin loading dose group (P < 0.05).The total effective rate of Atorvastatin loading dose group was significantly higher than that of atorvastatin normal dose group and Rosuvastatin loading dose group (P 0.05).The incidence of adverse reactions in the conventional dose of Rosuvastatin group was significantly higher than that of the normal dose group of Atorvastatin, Atorvastatin loading dose group, Rosuvastatin loading dose group (P < 0.05).The conventional dose of Rosuvastatin and Atorvastatin loading dose can play an equal role in improving the lipid profile of patients.The conventional dose of Rosuvastatin can improve the clinical effect and has higher safety.